Dr Shane Gangatharan provides an overview of Hodgkin Lymphoma, focusing on the therapies for early, advance, relapsed and refractory Hodgkin Lymphoma. This 1.5-hours module also looks at current evidence supporting therapies and describes the potential future therapeutic directions for Hodgkin Lymphoma.
Course Description
Course Details
Expiry Date: 2021-03-31
Professions: Specialist
Faculty
Dr Shane Gangatharan
MBBS, FRACP, FRCPA
Haematologist
Fiona Stanley Hospital, Perth, WA
Senior Clinical Lecturer, University of Western Australia, Perth, WA
Accreditation
The curriculum is endorsed by the RACP/RCPA Committee for Joint College training in Haematology (CJCT) and the Haematology Society of Australia and New Zealand (HSANZ). Fellows of the RACP may claim CPD hours under the CPD Program (CPDP).
Learning Objective(s)
At the end of this module, you will be better able to:
- Describe the assessment and classification of Hodgkin Lymphoma
- Define therapies for early stage and advanced stage Hodgkin Lymphoma, and for relapsed or refractory Hodgkin Lymphoma
- Explain the follow-up of Hodgkin Lymphoma and the management of late effects
- Discuss the evidence supporting therapies for Nodular Lymphocyte Predominant Hodgkin Lymphoma
- Describe potential future therapeutic directions for Hodgkin Lymphoma